スポンサーリンク
大阪大学 医学系研究科機能診断科学 | 論文
- Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
- Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors
- Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer
- Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas
- Wilms Tumor Gene WT1 Peptide-Based Immunotherapy Induced a Minimal Response in a Patient with Advanced Therapy-Resistant Multiple Myeloma
- WT1_, a Ninemer Peptide Derived from Wilms' Tumor Gene Product, Is a Candidate Peptide for the Vaccination of HLA-A^*0201-Positive Patients with Hematopoietic Malignancies
- WT1 Peptide-Based Immunotherapy for Patients with Lung Cancer : Report of Two Cases
- Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leulemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis
- The lck Promoter-Driven Expression of the Wilms Tumor Gene WT1 Blocks Intrathymic Differentiation of T-Lineage Cells
- Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
- Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma
- Positron Emission Tomography/Computed Tomography after Immunocytochemical and Clonal Diagnosis of Intraocular Lymphoma with Vitrectomy Cell Blocks
- Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
- Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
- Pulmonary Coccidioidomycosis That Formed a Fungus Ball with 8-years Duration
- Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma
- Frequent downregulation or loss of CD79a expression in plasma cell myelomas : Potential clue for diagnosis
- Immunoglobulin G4 (IgG4)-Positive or -Negative Ocular Adnexal Benign Lymphoid Lesions in Relation to Systemic Involvement
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)